Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Payables (2020 - 2025)

RxSight's Payables history spans 6 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Payables rose 16.55% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 16.55%, while the annual FY2025 figure was $5.3 million, 16.55% up from the prior year.
  • Payables reached $5.3 million in Q4 2025 per RXST's latest filing, up from $3.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.1 million in Q1 2025 to a low of $1.7 million in Q4 2021.
  • Average Payables over 5 years is $3.8 million, with a median of $3.9 million recorded in 2023.
  • Peak YoY movement for Payables: soared 146.72% in 2022, then crashed 34.29% in 2025.
  • A 5-year view of Payables shows it stood at $1.7 million in 2021, then skyrocketed by 53.64% to $2.6 million in 2022, then surged by 48.86% to $3.9 million in 2023, then increased by 17.63% to $4.5 million in 2024, then increased by 16.55% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Payables are $5.3 million (Q4 2025), $3.4 million (Q3 2025), and $3.3 million (Q2 2025).